title: Bordetella holmesii endocarditis in a patient with systemic lupus erythematous treated with immunosuppressive agents.
authors.forename: Matteo
authors.initials: M
authors.lastname: Bassetti
authors.forename: Elena
authors.initials: E
authors.lastname: Nicco
authors.forename: Daniele Roberto
authors.initials: DR
authors.lastname: Giacobbe
authors.forename: Anna
authors.initials: A
authors.lastname: Marchese
authors.forename: Erika
authors.initials: E
authors.lastname: Coppo
authors.forename: Ramona
authors.initials: R
authors.lastname: Barbieri
authors.forename: Claudio
authors.initials: C
authors.lastname: Viscoli
mesh_terms: D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001884:Bordetella / Q000145:classification / Q000302:isolation & purification*; D001885:Bordetella Infections / Q000150:complications / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004697:Endocarditis, Bacterial / Q000150:complications / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D006785:Hospitals, University; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007558:Italy; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone